JP Morgan Maintains Neutral on LifeStance Health Gr, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill has maintained a Neutral rating on LifeStance Health Group (LFST) but has reduced the price target from $10 to $8.

November 17, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
LifeStance Health Group's price target has been lowered from $10 to $8 by JP Morgan, although the Neutral rating is maintained.
A lowered price target can often lead to a negative perception of the company's future stock performance, potentially causing a short-term decline in the stock price. However, since the rating remains Neutral, the impact may be somewhat mitigated.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100